Targets › FFAR1
2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 3; Psychiatry, Infectious disease; next expected readout Dec 2026.
G protein-coupled receptor for medium and long chain saturated and unsaturated fatty acids that plays an important role in glucose homeostasis. Fatty acid binding increases glucose-stimulated insulin secretion, and may also enhance the secretion of glucagon-like peptide 1 (GLP-1). (UniProt, O14842)
Open in Phaseline: the race on FFAR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Samuel Fortin | Monoglyceride Eicosapentaenoic acid (MAG-EPA) Omega-3 fatty acid that activates free fatty acid receptors and reduces inflammation throu | FFAR1, FFAR4 | Phase 4 | Brain Fog | May 2027 |
| Ottawa Heart Institute Research Corporation | Icosapent Ethyl (Vascepa) Triglyceride-lowering agent; omega-3 fatty acid | FFAR1, FFAR4 | Phase 3 | Inflammation | Dec 2026 |
Brain Fog (1) Inflammation (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.